Muscular Dystrophy, Duchenne
Conditions
Keywords
duchenne, dystrophy, DMD, clinical trial, CINRG
Brief summary
This study will help to determine the safety and efficacy of the nutritional supplement Coenzyme Q10 when added to steroids as a treatment for Duchenne muscular dystrophy (DMD). Boys with DMD who are enrolled in this study will should be on a stable dose of steroids for at least six months, and will remain on their usual dose throughout the study. They will complete two screening visits within a one-week period, and if enrolled will then have their strength tested monthly for three months before beginning therapy with Coenzyme Q10. Once Coenzyme Q10 therapy is started, participants will have their strength tested monthly for six months. Following the six month treatment period, participants will be given the option to remain on Coenzyme Q10 until the study is completed.
Interventions
DRUGCoenzyme Q10
Sponsors
Cooperative International Neuromuscular Research Group
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
5 Years to 11 Years
Healthy volunteers
No
Inclusion criteria
Subject Inclusion Criteria 1. Age: 5 - 11 years old 2. Ambulant 3. Diagnosis of DMD confirmed by at least one the following: * Positive X-linked family history for typical Duchenne muscular dystrophy in older male relatives (onset by age 5 yr., wheelchair-bound by age 12 yr.) OR * Dystrophin immunofluorescence and/or immunoblot showing complete dystrophin deficiency, and clinical picture consistent with typical Duchenne dystrophy OR * Gene deletion test positive (missing one or more exons) in the central rod domain (exons 25-60) of dystrophin, where reading frame can be predicted as 'out-of-frame', and clinical picture consistent with typical Duchenne dystrophy. 4. On Glucocorticosteroids: Children must be on a steady dose of prednisone or deflazacort, on any schedule (Daily, alternate days, 10 days on, 10 days off or twice a week), for the last 6 months before starting the clinical trial. Dose of steroid or schedule cannot be altered during the study. 5. Evidence of muscle weakness by MRC score or clinical functional evaluation 6. Ability to provide reproducible repeat QMT bicep score within 10% of first assessment score. 7. Ability to swallow tablets Subject
Exclusion criteria
1. Failure to achieve one or more of the diagnostic inclusion criteria cited above. 2. Symptomatic DMD carrier 3. Previous (6 months or less) or current use of Coenzyme Q10 (for DMD or any other disease) 4. Use of carnitine, other amino acids, creatine, glutamine, or any herbal medicines within the last 3 months. 5. History of significant concomitant illness or significant impairment of renal or hepatic function.
Countries
United States
Outcome results
None listed